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Introduction
Ischemic stroke represents one of the most frequent causes of death 
and leading causes of disability worldwide (1). Thrombolytic or 
mechanical removal of the occlusion is the only therapeutic option 
(2). In 11% of the mechanically recanalized patients, however, seri-
ous complications occur (3), and thrombolysis using tissue plasmin-
ogen activator (rtPA) correlates with an early opening of the blood-
brain barrier (BBB), edema, and hemorrhagic transformation, with 
excessive ROS production and worse prognosis (4). Importantly, an 
increase in intracellular calcium represents one of the earliest events 
during this scenario (2, 5). Pharmacological agents that selectively 
inhibit the activity of ROS-forming enzymes, i.e., NADPH oxidase, 
are active in poststroke models (6). Antioxidants have been used to 
restore redox imbalances and improve disease outcomes, although 
with mostly ineffective results (6, 7). We therefore implemented an 
innovative approach that uses pharmacological agents that selec-
tively inhibit the activity of ROS-forming enzymes (8).
NADPH oxidases are considered a primary and quantitatively 
relevant source in different ischemic conditions (5). Of particu-
lar interest is NADPH oxidase type 5 (NOX5), the only calcium- 
activated isoform widely expressed in endothelium (7), testis, and 
WBCs (8). We hypothesized that NOX5 may be the missing link 
between postreperfusion calcium overload and early BBB open-
ing. Since NOX5 is missing from the mouse genome, we generated 
a humanized mouse model expressing the human NOX5 gene. 
To validate its role in acute recanalization, we examined both a 
pharmacological approach in a human in vitro BBB model and a 
genetic approach in an in vivo stroke model in mice.
Results and Discussion
Generation and validation of a humanized NOX5-KI mouse model. 
In humans, NOX5 is broadly expressed in vascular endothelium, 
fibroblasts (7, 9, 10), testis (9), and spleen monocytes, macro-
phages (8, 11), B cells, and T cells (12). To mimic the physiological 
human expression pattern of NOX5 in mice, we created a mouse 
line called NOX5-knockin (NOX5-KI), bearing the human NOX5 
gene under control of the Tie2 promoter (Figure 1, A and B). The 
Tie2 promoter physiologically regulates endothelial and hema-
topoietic gene expression in human cells (13, 14). Therefore, we 
expected our transgenic mouse model to mimic physiological 
human NOX5 expression.
Tissues from WT mice did not show any detectable NOX5 
gene expression, while significant expression was detected in all 
KI mice (Figure 1C), primarily in lung, kidney, brain, aorta, and 
WBCs (monocytes, lymphocytes, T and B cells; Supplemental 
Figure 1; supplemental material available online with this arti-
cle; https://doi.org/10.1172/JCI124283DS1). Thus, our Tie2-
NOX5-KI mouse model is ideally humanized with respect to the 
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In vitro, NOX5 causes acute, calcium-dependent postreoxygen-
ation ROS formation. With respect to ischemic stroke, delayed 
induction of NOX4 was identified as a relevant source of ROS (5, 
17), but neither NOX1 nor NOX2 was identified as such (18), and 
the role of NOX5 is unclear. To examine whether NOX5 is relevant 
for ROS formation upon cerebral reoxygenation, we first studied 
in vitro organotypic hippocampal cultures (OHCs) from NOX5-KI 
and WT mice. To detect ROS species as broadly as possible, includ-
ing secondary reactions and not differentiating among superox-
ide, hydrogen peroxide, hydroxyl, or possibly peroxynitrite, we 
chose the dihydroethidium (DHE) method, as published previ-
ously (17, 19). Fifteen minutes of oxygen and glucose deprivation 
(OGD) (Figure 2A) resulted, unlike with NOX4, in an acute NOX5- 
physiological expression patterns in humans, i.e., endothelial 
cells and WBC. Of note, WBCs are an independent predictor 
of outcome after ischemic stroke (15). Leukocyte counts may 
independently predict the risk of suffering from an ischemic 
event (16). Importantly, the leukocyte proportions in NOX5-KI 
mice were indistinguishable from those in WT mice, indicating 
no major phenotype change (Supplemental Table 1 and Supple-
mental Table 2). Subgroup analysis revealed only a single sub-
stantial observation, an increase in the CD4+ to CD8+ T cell ratio 
in females. Thus, any phenotype in our NOX5-KI mouse model 
will be most likely of endothelial rather than immune cell origin. 
No phenotype was observed with respect to life span, cognition, 
or neuromotor function.
Figure 1. Generation and validation of the NOX5-KI mouse. (A) Representative schematic of the humanized NOX5 mice. NOX5 gene located on the 
X chromosome results in females with a double copy of the gene (NOX5-KI/KI), while gene load is half in male mice (NOX5-KI/Y) (B) Construction of the 
humanized NOX5-KI mice. First, WT and deleted Hprt constructs are shown. The targeting vector to insert NOX5 (human NOX5 cDNA, blue box) was 
coupled to the human Hprt promoter (red box) and exons 1 and 2. The human Hprt promoter is under control of the Tie2 gene (purple box) to create NOX5 
expression. Hatched black and red boxes represent murine and human Hprt exons, respectively. Solid line represents intronic sequences. (C) NOX5 gene 
expression was measured by qPCR (Ct) in different organs (lung, brain, kidney, aorta, and mouse brain capillary endothelial cells [MBCEC]); macrophages 
from bone marrow (undifferentiated [M0], inflammatory [M1], and active [M2]); and hematopoietic cells isolated from spleen (monocytes [Mono], 
neutrophils [Neu], B cells, and T cells). Tissues from WT mice did not show NOX5 gene expression, while significant expression was detected in NOX5-KI 
mice. Ct values of n = 4 are shown.
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translational parameter, neuromotor function. Importantly, post-
stroke NOX5-KI mice, when compared with WT mice, showed a 
significant increase in infarct volume (Figure 3D) and worsened 
Bederson score and grip tests (Figure 3, E and F; see Supplemental 
Methods). Thus, acute postreoxygenation Ca2+-dependent ROS 
formation, BBB breakdown, increased infarct size, and worsened 
neuromotor outcome are mechanistically linked to NOX5.
Blood pressure does not contribute as a confounder to the NOX5-
KI phenotype in stroke. Conceivably, an endothelial NOX5-KI may 
lead to a systemic constitutively elevated endothelial ROS forma-
tion linked to increased blood pressure. Hypertension can weaken 
brain arteries and indirectly worsen stroke outcome (21), which 
may result in possible overestimation of direct NOX5 impact. 
We therefore also assessed blood pressure over 24 hours using 
telemetric devices. Neither systolic, diastolic, nor mean arterial 
pressure (Supplemental Figure 2, A–C) were different between 
WT and NOX5-KI mice, suggesting that no systemic hypertensive 
phenotype confounded the worsened postreperfusion in vivo out-
come in NOX5-KI mice.
The role for NOX5-KI in ischemia reperfusion is specific to the 
brain. In principle, knocking in NOX5 in the vascular endothelium 
may worsen outcomes in many ischemia-reperfusion (IR) scenarios 
in different organs and thus play no brain-specific role. Indeed, 
for NOX1 and NOX2, such roles have been described in myocar-
dial infarction (MI) (22), retinopathy (23), or diabetic nephropathy 
(24, 25). Moreover, NOX5 is upregulated in human blood vessels 
after MI (26). We therefore investigated in vivo 3 different relevant 
ischemic-disease conditions: hindlimb ischemia (HL, peripheral 
artery disease), MI, and IR of the heart.
dependent ROS production within the first 30 minutes that was not 
present in WT mice (Figure 2, B and C). At later time points, ROS 
formation was unchanged, presumably due to the known, delayed 
induction of NOX4 (20). To confirm that the early spike in ROS was 
indeed due to calcium-induced activation of NOX5, we reexam-
ined ROS generation in OHCs from NOX5-KI and WT mice in the 
absence or presence of the calcium ionophore A23187 (10 μM), but 
without OGD. Indeed, we observed the same acute ROS surge as 
seen after OGD and in a strictly NOX5-dependent manner (Figure 
2, D and E). Thus, NOX5-dependent ROS formation is involved in 
early stages after ischemia via a Ca2+-dependent mechanism.
In vivo, ROS formation and BBB breakdown are NOX5 dependent 
and worsen neurological outcome. To examine the role of NOX5 in a 
stroke in vivo, we performed a 1-hour transient occlusion of the mid-
dle cerebral artery (tMCAO) on adult mice, followed by 24 hours 
of reperfusion (Figure 3A) for histological and neurological assess-
ment. Reperfusion injury leads to an abnormally permeable capillary 
bed, resulting in a disruption of the BBB (4). BBB leakage was sig-
nificantly increased in brains from NOX5-KI mice when compared 
with their WT littermates, indicating also here a key role for NOX5 
in poststroke BBB integrity (Figure 3B). To examine the mechanistic 
link between this observation and NOX5 activity, we measured ROS 
formation in NOX5-KI and WT mice. Again, ROS generation was 
significantly increased in poststroke NOX5-KI mice compared with 
controls (Figure 3C). Thus, poststroke NOX5-dependent impair-
ment of the BBB is related to enhanced in vivo ROS formation.
To further evaluate, 24 hours after stroke, whether NOX5- 
dependent ROS formation and impairment of the BBB were linked 
to a worsened outcome, we assessed infarct sizes and, as a clinical 
Figure 2. Increased in vitro ROS 
production is related to Ca2+ overload 
and NOX5. (A) In vitro, mouse OHCs 
were subjected to OGD, followed by the 
reoxygenation period. (B) ROS production 
measured after OGD in OHCs was higher 
in NOX5-KI mice (blue, n = 6) versus 
NOX5 WT mice (black, n = 6), starting 
directly from the OGD period until 4 hours 
after OGD. **P < 0.01, Bonferroni’s mul-
tiple comparison test. (C) Difference in 
ROS production between NOX5-KI (blue, 
n = 6) and WT (black, n = 6) mice showed 
a NOX5-dependent effect within the first 
hour after OGD (0, 0.25, 0.5, and 1 hour). 
(D) Addition of the ionophore A23187 (10 
μM) showed a Ca2+-dependent increase 
in ROS formation in NOX5-KI mice (blue, 
n = 3, Bonferroni’s multiple comparison 
test), while no changes were detected 
in WT mice (black, n = 3). *P < 0.05. (E) 
Difference in ROS production between 
NOX5-KI (blue, n = 3) and WT (black,  
n = 3) mice showed a direct link between 
Ca2+ overload and NOX5 induction at 15 
and 30 minutes after A23187.
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To test the translatability of our findings into the clinical setting, 
i.e., pharmacological intervention, we used a primary culture of 
human brain microvascular endothelial cells (HBMECs) as an in 
vitro ischemia model (Figure 4A). Importantly, thrombectomy 
procedures have been recently associated with reperfusion dam-
age and early BBB disruption, hemorrhagic transformation, and 
poor clinical outcomes. Thus, clinical trials have been designed 
to pharmacologically block the BBB opening in patients undergo-
ing poststroke recanalization (4). Here, calcium is critical for tight 
junction function, particularly for cerebral microvessels and BBB 
stability, and poststroke calcium overload is a key mechanism of 
BBB disruption. Thus, we hypothesized that NOX5 is the missing 
mechanistic link in early BBB disruption and reperfusion injury. 
We subjected HBMECs expressing NOX5 endogenously to 6 hours 
of hypoxia, followed by 24 hours of reoxygenation and assessment 
of cell permeability (Figure 4B) in the presence or absence of the 
relatively NOX5-specific inhibitor ML090 (0.01 μM; Supplemen-
tal Figure 4). Importantly, delayed induction of NOX4 also con-
tributes to BBB disruption (17) and needed to be taken into con-
sideration (Supplemental Figure 5). Hence, HBMECs were also 
treated both acutely and after reoxygenation with the relatively 
NOX4-specific inhibitor M13 (0.2 μM) (Figure 4C). While the 
NOX4 inhibitor was protective when added either early or late, 
the NOX5 inhibitor was only protective when added early (Figure 
4D). To finally test the possibility of a role for calcium-dependent 
To mimic human peripheral artery disease, we subjected 
NOX5-KI and WT mice to permanent ligation of the femoral artery, 
with angiogenesis being commonly used as a major histological 
outcome (27). Four weeks after occlusion, however, CD31 staining 
was comparable between WT and NOX5-KI mice (Supplemental 
Figure 3, A and B) as was blood flow (Supplemental Figure 3C).
To further investigate the role of NOX5 in MI and IR of the 
heart, we subjected adult NOX5-KI and WT mice to a perma-
nent or transient occlusion of the left descending coronary artery. 
Again, 4 weeks after MI or IR, infarct sizes showed no differenc-
es between NOX5-KI and WT mice (Supplemental Figure 3D); 
2 and 4 weeks after MI or after IR, ejection fraction, a common 
functional parameter, did not differ between NOX5-KI and WT 
mice (Supplemental Figure 3E). Finally, we examined cardiac 
contractility in response to increasing concentrations of the 
sympathomimetic dobutamine. NOX5-KI mice subjected to MI 
showed slightly enhanced contractility and relaxation. Upon IR, 
however, the response to dobutamine was not altered (Supple-
mental Figure 3F). Thus, in our humanized NOX5-KI mice, nei-
ther postischemic outcomes after permanent and/or transient 
ischemia of the heart nor long-term outcomes after HL were mod-
ified. These data suggest that the acute effects of NOX5 on ROS 
formation, infarct volume, and function are brain specific.
Acute postreoxygenation leakiness of human microvascular brain 
endothelial cells is prevented by pharmacological NOX5 inhibition. 
Figure 3. NOX5 leads to increased stroke size and BBB damage and aggravates neuromotor function. (A) In vivo, tMCAO was performed in WT and  
NOX5-KI mice. (B) Evans blue staining 24 hours after tMCAO showed BBB damage in both WT (black, n = 18) and NOX5-KI (blue, n = 11) mice. *P < 0.05, 
2-tailed unpaired t test. (C) ROS production as measured by DHE staining 24 hours after stroke induction was increased in NOX5-KI (blue, n = 4, 2-tailed 
unpaired t test) versus NOX5 WT (black, n = 4) mice. *P < 0.05. Original magnification, ×40. (D) Increased infarct sizes are shown in NOX5-KI (blue, n = 16) 
versus NOX5 WT mice (black, n = 21). ***P < 0.001, 2-tailed unpaired t test. Neurological behavior testing showed worse neurological functioning in  
NOX5-KI (blue, n = 19) versus WT (black, n = 22) mice, with worse (E) Bederson and (F) grip test scores. *P < 0.05, 2-tailed unpaired t test. Data are repre-
sented as mean ± SEM in all experiments. Representative photographs are shown above the graphs.
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the first humanized NOX5-KI mouse model that mimics, to a 
large extent, the physiological pattern of NOX5 expression in 
humans, with substantial expression in endothelial cells and 
WBCs. In principle, our observed in vivo phenotype in NOX5-KI 
mice could thus derive from endothelial cells and WBCs, and we 
certainly cannot completely rule out a contribution of the lat-
ter. However, several lines of evidence support a fully sufficient 
role of endothelial NOX5. First, our in vitro mouse organotypic 
culture, essentially free of WBC contributions, and second, our 
HBMEC model, per definition entirely free of WBCs, are in full 
agreement with a crucial endothelial location of NOX5. Third, 
the detrimental role of NOX5 after reperfusion was highly spe-
cific for brain; NOX5 played no acute role in MI, transient heart 
ischemia, or HL, suggesting indirectly the BBB and its cellular 
components as the main location of NOX5. Moreover, endothe-
lial NOX5 would already be at the site of action with respect to 
BBB breakdown, whereas WBCs would need to adhere, and only 
a fraction of them would be preexposed to postreperfusion cal-
PKC and direct NOX2 activation (28), HBMECs were also treat-
ed before reoxygenation with the PKC inhibitor GF109203X (0.3 
μM), which, however, showed no effect, suggesting no relevant 
role of NOX2 (Supplemental Figure 6), in agreement with a pre-
vious in vivo preclinical randomized confirmatory trial (18). Thus, 
the role of calcium in acute BBB breakdown after reoxygenation/
reperfusion in stroke can be fully explained by NOX5, while NOX4 
induction plays a key role in later stages. The efficacy of ML090 
suggests a preventive pharmacotherapeutic option, ideally as a 
pretreatment or through coadministration with a thrombolytic 
drug, i.e., rtPA or a thrombectomy procedure.
Thus, we here identify NOX5-derived ROS as a missing link 
in acute stroke therapy between postreperfusion calcium surge, 
BBB breakdown, and worsened outcome. NADPH oxidases in 
general are promising therapeutic targets in ROS-associated dis-
eases (5, 6, 29). Since most preclinical validation experiments 
are conducted in mice and rats, which lack the NOX5 gene, 
NOX5 has been understudied. We provide what we believe is 
Figure 4. NOX5 inhibition before reoxygen-
ation reduced cell permeability to basal 
levels using a human in vitro ischemia 
model. (A) HBMECs were seeded on Tran-
swell inserts, where cell permeability was 
assessed using Evans blue dye. (B) After 
incubation and seeding under normoxic 
conditions, HBMECs were subjected to 6 
hours of hypoxia and 24 hours of reoxygen-
ation. Cells were treated with both NOX4 
(M13) and NOX5 inhibitors (ML090) at early 
(20 minutes before reoxygenation) and 
late (20 minutes after reoxygenation) time 
points. (C) Cell permeability was assessed 
by measuring Evans blue fluorescence 
after hypoxia. Evans blue diffusion was 
significantly reduced in cells subjected to 
early treatment of ML090 (0.01 μM), which 
preferably inhibits NOX5, and M13 (0.2 μM), 
which is mainly a NOX4 inhibitor  
(*P < 0.05, 2-tailed unpaired t test). In 
contrast, late treatment was only effective 
after M13 (0.2 μM) treatment compared 
with that of nontreated cells (##P < 0.01). 
Reox, reoxygenation. (D) NOX5 activation 
takes place within the first 30 minutes to 
1 hour after hypoxia (see Figure 3), while 
NOX4 activation peak appears at around  
5 hours after ischemia (20). Data are repre-
sented as mean ± SEM in all experiments. 
NOX4i, NOX4 inhibitor.
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cium surges. We also cannot exclude the possibility that NOX5 
in other nonendothelial or non-WBC types may also contribute 
in vivo. From a clinical translational point of view, this may be a 
minor limitation because NOX5-directed pharmacotherapies, 
e.g., small molecules such as ML090, will always act systemically 
and not in a cell-specific manner.
Therapeutically, one additional aspect is worth considering, 
i.e., the previous identification of neuronal (and endothelial) 
NOX4 in stroke (17, 19). This enzyme does not contribute to the 
here-investigated early stages of BBB opening. Therefore, any pro-
spective therapy will ideally want to cover both isoforms, acutely 
induced NOX5 and subacutely (i.e., within 4 to 6 hours) induced 
NOX4, to further inhibit the detrimental role of NOX4 and NOX5 
at different stages of the pathomechanism.
Of direct clinical importance, our data suggest that throm-
bolysis and thrombectomy should be conducted in the presence 
of NOX inhibition to minimize the chances of a postreperfusion, 
calcium- and ROS-dependent acute and deleterious opening of 
the BBB. Our findings provide a clear rationale for further devel-
opment of a pharmacological NOX4/5 inhibitor as a first-in-class 
neuroprotective strategy after stroke, to be coadministrated with 
the onset of reperfusion.
Methods
Details are provided in the Supplemental Methods.
Statistics. All data are expressed as mean ± SEM. Statistical differ-
ences between mean continuous values were determined by Student’s 
2-tailed t test. For repeated measurements, 2-way ANOVA was used.
Study approval. All animal experiments were performed according 
to the EU Directive 2010/63/EU for animal experiments, the German 
Animal Welfare Act, and Dutch law on animal experiments (Centrale 
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